Showing 8831-8840 of 10547 results for "".
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- NPF Launches New Resource for Youth with Psoriasis, Psoriatic Arthritishttps://practicaldermatology.com/news/npf-launches-new-resource-for-youth-with-psoriasis-psoriatic-arthritis/2457949/Our Spot, a new resource launched by The National Psoriasis Foundation (NPF), provides resources for kids and teens living with psoriasis and psoriatic arthritis. The program includes a
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- FDA Warns that Biotin May Interfere with Lab Test Resultshttps://practicaldermatology.com/news/fda-warns-that-biotin-may-interfere-with-lab-test-results/2457961/Biotin may significantly interfere with certain lab tests and cause "clinically significant incorrect lab test results," the US Food and Drug Administration warns. At least 1 death has been related to biotin interference with laboratory results, FDA officials wrote in a Saf
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Obagi Eyes the Future Under New Ownershiphttps://practicaldermatology.com/news/obagi-eyes-the-future-under-new-ownership/2457973/The sale of Obagi Medical Products to the Haitong International Zhonghua Finance Acquisition Fund I, L.P. and limited partners China Regenerative Medicine International (CRMI) Ltd. is now complete. The new
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- Isdin Introduces Two New Productshttps://practicaldermatology.com/news/isdin-introduces-two-new-products/2457977/ISDIN is rolling out ISDIN Age Contour plus a new shade in their ISDINCEUTICS Skin Drops collection. ISDIN AGE CONTOUR is a triple-action face and neck cream that aims to reduce jawline sagging and glycation in the skin as well as protect&nb
- Is a Topical Gel Made From Oral Blood Pressure Drugs a Panacea for Wound Healing, Wrinkles and More?https://practicaldermatology.com/news/is-a-topical-gel-made-from-oral-blood-pressure-drugs-a-panacea-for-wound-healing-wrinkles-and-more/2457989/Topical gel made from angiotensin II receptor blockers may speed the healing of chronic skin wounds in mice and pigs, Johns Hopkins researchers report. The findings, published in the Journal of Investigative Dermatology, marks efforts to seek approval from the U.S. Food and Drug